Expression of serum alpha fetoprotein heterogeneity in chronic liver disease and its diagnostic value for hepatocellular carcinoma
10.3760/cma.j.cn112866-20190716-00112
- VernacularTitle:血清甲胎蛋白异质体在慢性肝病中的表达及对肝癌的诊断价值探讨
- Author:
Jingdi ZHOU
1
;
Xin HUA
;
Yaoren HU
;
Guosheng GAO
Author Information
1. 中国科学院大学宁波华美医院病员服务中心，宁波 315000
- Keywords:
Hepatocellular carcinoma;
Alpha-fetoprotein;
Alpha-fetoprotein heterogeneity
- From:
Chinese Journal of Experimental and Clinical Virology
2020;34(5):527-531
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the expression of alpha fetoprotein (AFP)-L3 in chronic liver disease and its diagnostic value for hepatocellular carcinoma.Methods:From October 2013 to March 2019, 341 patients with liver diseases in Huamei Hospital, University of Chinese Academy of Sciences were selected, including 88 cases of chronic hepatitis, 97 cases of cirrhosis, 145 cases of hepatocellular carcinoma (60 cases of initial onset, 39 cases of recurrence, 23 cases treated by transcatheter arterial chemoembolization, 23 cases treated by surgery and radiofrequency therapy) and 11 cases with acute-on-chronic liver failure. The difference of AFP and AFP-L3 (%) levels between different groups was compared. The diagnostic efficacy of AFP-L3 (%) for hepatocellular carcinoma was analyzed by using receiver operating curve (ROC).Results:There were significant differences in serum AFP-L3 (%) and AFP between patients with hepatitis, cirrhosis, acute-on-chronic liver failure and hepatocellular carcinoma (initial onset) (Hc=28.384, 9.913, P=0.001, 0.019). Post hoc multiple comparisons showed that the serum AFP-L3 (%) levels of patients with hepatocellular carcinoma (initial onset) were higher than those of patients with hepatitis and cirrhosis (all P<0.05). The level of serum AFP in patients with hepatocellular carcinoma (initial onset) was higher than that of patients with cirrhosis ( P<0.05), but there was no significant difference between patients with hepatocellular carcinoma (initial onset) and patients with acute-on-chronic liver failure for AFP-L3 (%) and AFP (all P>0.05). The levels of AFP-L3 (%) and AFP in patients with recurrence of hepatocellular carcinoma were significantly higher than those in patients undergoing hepatocellular carcinoma surgery and radiofrequency therapy ( P<0.05). Tumor size and TNM stage affected serum AFP level (all P<0.05), but etiology, tumor size and number, tumor thrombus, CTP score and TNM stage had little relationship with serum AFP-L3 (%) (all P>0.05). The diagnostic value of serum AFP-L3 (%) was better than that of AFP ( Z=2.637, P=0.008); the best cut-off value of AFP-L3 in the diagnosis of hepatocellular carcinoma was 6.10%, and the specificity and sensitivity were 76.63% and 61.29%, respectively. Conclusions:The diagnostic value of serum alpha-fetoprotein heterogeneity in hepatocellular carcinoma is better than that of AFP, which is less affected by pathological factors. In order to improve the diagnostic efficiency, we can establish reliable cut-off value by validating large samples in the laboratory.
